These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27450227)

  • 1. A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.
    Lukacova V; Goelzer P; Reddy M; Greig G; Reigner B; Parrott N
    AAPS J; 2016 Nov; 18(6):1453-1463. PubMed ID: 27450227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.
    Jorga K; Chavanne C; Frey N; Lave T; Lukacova V; Parrott N; Peck R; Reigner B
    Clin Pharmacol Ther; 2016 Dec; 100(6):761-769. PubMed ID: 27530217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
    Jung D; Dorr A
    J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
    Vezina HE; Brundage RC; Balfour HH
    Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
    Pescovitz MD
    Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
    Malmborg J; Ploeger BA
    J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
    Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.
    Carmichael RJ; Whitfield C; Maxwell LK
    J Vet Pharmacol Ther; 2013 Oct; 36(5):441-9. PubMed ID: 23301502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
    Kroes AC
    Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.
    Sugawara M; Huang W; Fei YJ; Leibach FH; Ganapathy V; Ganapathy ME
    J Pharm Sci; 2000 Jun; 89(6):781-9. PubMed ID: 10824137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design.
    Tirucherai GS; Dias C; Mitra AK
    J Ocul Pharmacol Ther; 2002 Dec; 18(6):535-48. PubMed ID: 12537680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children.
    Vethamuthu J; Feber J; Chretien A; Lampe D; Filler G
    Pediatr Transplant; 2007 May; 11(3):301-5. PubMed ID: 17430487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS.
    Xu HR; Li XN; Chen WL; Liu GY; Chu NN; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):329-34. PubMed ID: 17126086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients.
    Launay E; Théôret Y; Litalien C; Duval M; Alvarez F; Lapeyraque AL; Phan V; Larocque D; Poirier N; Lamarre V; Ovetchkine P
    Pediatr Infect Dis J; 2012 Apr; 31(4):405-7. PubMed ID: 22198827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.